SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

New RAMP 201 analyses of Verastems avutometinib/defactinib combination in recurrent low-grade serous ovarian cancer are drawing interest, particularly the reported activity in KRAS wild-type patients and whether it could broaden the treatment opportunity. Traders are also focused on the planned VS-7375 KRAS G12D update across several cancers, weighing its potential against competing drugs and the need for convincing efficacy and tolerability data.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally and breakout on heavy volume has sparked bullish momentum chatter alongside concerns about profit-taking and whether support will hold. Traders link renewed interest to Starknets consideration of an independent L1 transition and its quantum-resistance, privacy, and Bitcoin DeFi ambitions, though the L1 shift remains a possibility rather than a completed change.

TOSHI

TOSHI is drawing attention around repeated attempts to break chart resistance, with some traders citing rising volume and renewed buying as signs of a possible breakout or short squeeze. Others remain skeptical, pointing to prolonged sideways or weak price action; bullish calls and listing speculation remain unconfirmed.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

Traders are discussing SQQQ as a leveraged hedge or bearish bet on the Nasdaq, citing concerns about stretched tech valuations, AI spending and a possible market pullback. Views are divided, with some expecting further tech strength and others warning that SQQQs daily leverage and decay make it risky to hold for long periods.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes BLA submission for sonelokimab in hidradenitis suppurativa has focused discussion on whether the FDA will accept the application and grant priority review. Traders are divided: some see regulatory progress and the drugs potential as a catalyst, while others point to disappointing IZAR results, dilution and management concerns, and question whether MoonLake can commercialize the drug alone or needs a partner or buyer.

Select Sector SPDR Trust (The) - State Street Health Care Select Sector SPDR ETF

Health Care Select Sector SPDR Fund

XLV is drawing attention for its rebound from a recent pullback into technical support, with many traders describing buyers stepping in and the bullish trend remaining intact. The broader discussion also points to healthcares role in a rotation toward defensive sectors, though some traders remain cautious about further correction or uneven sector strength.

BNB is the native utility token of the BNB Chain ecosystem, acting as a multi-chain asset that powers decentralized applications and facilitates value exchange across its network. It serves as the primary asset for paying transaction gas and smart contract deployment fees while providing users with tiered fee discounts on the Binance exchange. The project’s main value proposition lies in its unified multi-chain architecture, which integrates a smart contract platform, a Layer 2 scaling solution, and a decentralized data storage network into a cohesive settlement and data availability layer.  The network operates on a Proof of Staked Authority consensus mechanism, utilizing a group of 21 active validators known as the Cabinet to verify transactions and produce blocks every 3 seconds. Validators are elected daily based on the amount of BNB staked or delegated to them, and the system employs fast finality and slashing penalties to maintain security and integrity. To manage its long-term economy, the project uses a programmatic dual-burn strategy that permanently removes tokens through real-time fee destruction and quarterly buybacks.  Launched in 2017 by the Binance platform, the project initially distributed 50% of its 200 million token supply to the public, while the founding team received 40% and angel investors were allocated 10%. Though it began as a token on the Ethereum network, it eventually migrated to its own autonomous architecture that remains fully compatible with the Ethereum Virtual Machine. Today, the token's utility includes paying for network gas, participating in staking rewards, and enabling decentralized governance through which holders can vote on technical upgrades and economic changes.

Binance

BNB is drawing attention for choppy, range-bound trading and repeated technical-analysis posts framing the setup as consolidation. Traders are split between expecting the rebound to continue and warning of further weakness, with broader crypto-market optimism competing against bearish calls.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

The FDAs acceptance of Intellias Lonvo-z BLA for priority review is the main catalyst, bringing its one-time HAE gene-editing therapy closer to a regulatory decision and potential launch. Bulls view the milestone and Phase 3 results as validation, while skeptics point to financing and commercialization risks and note the stocks muted, volatile reaction.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Positive clinical data for Kyvernas miv-cel in stiff person syndrome and generalized myasthenia gravis, alongside progress toward an SPS BLA, is driving attention. Traders are weighing the therapys durability and safety against a sharp, volatile post-data reaction, with some attributing the pullback to profit-taking and potential dilution concerns.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

T-Mobile shares sold off sharply after SpaceX agreed to acquire low-band spectrum for Starlink Mobile, raising concerns that its satellite service could become a direct wireless competitor. Traders debate whether the threat merits a lasting valuation reset or whether the reaction overstates near-term risk given the infrastructure and capacity required to rival established carrier networks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$GOOGL: a 9-3 jury sided with Android users in July 2025, awarding $314.6M over alleged background cellular-data transfers. Google settled for $350M instead of appealing. No claim form; payouts automatic once approved. Open Class Actions.

StockTwits Web

Alphabet Inc Class A

: a 9-3 jury sided with Android users in July 2025, awarding $314.6M over alleged background cellular-data transfers. Google settled for $350M instead of appealing. No claim form; payouts automatic once approved. Open Class Actions.